Loading...

Pietras Richard

Title(s)Professor, Hematology-Oncology
Phone(310) 825-9769
vCardDownload vCard
    Other Positions
    Title(s)Professor, Medicine


    Collapse Research 
    Collapse Research Activities and Funding
    Development of New Therapeutics for Pancreatic Cancer Management
    NIH/NCI R21CA176337Jun 1, 2013 - May 31, 2015
    Role: Principal Investigator
    NEW ENDOCRINE THERAPY IN OLDER WOMEN WITH BREAST CANCER
    NIH/NIA R01AG014785Aug 15, 1997 - Jun 30, 2001
    Role: Principal Investigator
    GROWTH FACTOR RECEPTOR DIRECTED THERAPY IN CANCER
    NIH/NCI R29CA060835Feb 1, 1995 - Jan 31, 2000
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Márquez-Garbán DC, Deng G, Comin-Anduix B, Garcia AJ, Xing Y, Chen HW, Cheung-Lau G, Hamilton N, Jung ME, Pietras RJ. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. J Steroid Biochem Mol Biol. 2019 Jun 19; 193:105415. PMID: 31226312.
      View in: PubMed
    2. Márquez-Garbán DC, Gorrín-Rivas M, Chen HW, Sterling C, Elashoff D, Hamilton N, Pietras RJ. Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Lett. 2019 May 01; 449:66-75. PMID: 30771431.
      View in: PubMed
    3. Young PA, Pietras RJ. Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models. Transl Lung Cancer Res. 2018 Dec; 7(Suppl 4):S373-S376. PMID: 30705860.
      View in: PubMed
    4. Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018 Sep 21; 9(74):33912-33930. PMID: 30338035.
      View in: PubMed
    5. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 Sep; 123:91-98. PMID: 30089602.
      View in: PubMed
    6. Boonyaratanakornkit V, Hamilton N, Márquez-Garbán DC, Pateetin P, McGowan EM, Pietras RJ. Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol. 2018 05 05; 466:51-72. PMID: 29146555.
      View in: PubMed
    7. Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11). PMID: 29099049.
      View in: PubMed
    8. Yaghoubian JM, Adashek J, Yaghoubian-Yazi B, Nagar M, Toomari N, Pietras RJ, Ben-Zur UM. Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. Case Rep Cardiol. 2017; 2017:3628127. PMID: 28828188.
      View in: PubMed
    9. Deng X, Apple S, Zhao H, Song J, Lee M, Luo W, Wu X, Chung D, Pietras RJ, Chang HR. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget. 2017 Jun 13; 8(24):38294-38308. PMID: 28418843.
      View in: PubMed
    10. Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-ß-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460. PMID: 28337662.
      View in: PubMed
    11. Rankin J, Nagar M, Crosby J, Toomari N, Pietras R, Ben-Zur UM. Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep. 2016 Dec 03; 10(1):346. PMID: 27912791.
      View in: PubMed
    12. Kawprasertsri S, Pietras RJ, Marquez-Garban DC, Boonyaratanakornkit V. Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells. Cancer Lett. 2016 May 01; 374(2):279-91. PMID: 26892043.
      View in: PubMed
    13. Mah V, Alavi M, Márquez-Garbán DC, Maresh EL, Kim SR, Horvath S, Bagryanova L, Huerta-Yepez S, Chia D, Pietras R, Goodglick L. Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS One. 2015; 10(5):e0127600. PMID: 26001082; PMCID: PMC4441434.
    14. Hamilton N, Márquez-Garbán D, Mah V, Fernando G, Elshimali Y, Garbán H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Biologic roles of estrogen receptor-ß and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015; 2015:925703. PMID: 25874233.
      View in: PubMed
    15. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90. PMID: 27279236.
      View in: PubMed
    16. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8. PMID: 23399957; PMCID: PMC3573351.
    17. Kazmi N, Márquez-Garbán DC, Aivazyan L, Hamilton N, Garon EB, Goodglick L, Pietras RJ. The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag. 2012 Dec; 1(4):259-272. PMID: 23650476.
      View in: PubMed
    18. Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, Horvath S, Chia D, Garon E, Goodglick L, Pietras RJ. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011 Aug; 76(9):910-20. PMID: 21600232.
      View in: PubMed
    19. Mah V, Marquez D, Alavi M, Maresh EL, Zhang L, Yoon N, Horvath S, Bagryanova L, Fishbein MC, Chia D, Pietras R, Goodglick L. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer. 2011 Nov; 74(2):318-25. PMID: 21511357; PMCID: PMC3175023.
    20. Márquez-Garbán DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci. 2009 Feb; 1155:194-205. PMID: 19250205; PMCID: PMC2782616.
    21. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 01; 113(9):2385-97. PMID: 18819158.
      View in: PubMed
    22. Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ, Goodglick L. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007 Nov 01; 67(21):10484-90. PMID: 17974992; PMCID: PMC3581354.
    23. Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 2007 Aug 15; 13(16):4672-6. PMID: 17699844.
      View in: PubMed
    24. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 2008 Apr; 108(3):351-61. PMID: 17592774.
      View in: PubMed
    25. Márquez-Garbán DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007 Feb; 72(2):135-43. PMID: 17276470.
      View in: PubMed
    26. Pietras RJ. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist. 2006 Jul-Aug; 11(7):704-17. PMID: 16880230.
      View in: PubMed
    27. Sartippour MR, Pietras R, Marquez-Garban DC, Chen HW, Heber D, Henning SM, Sartippour G, Zhang L, Lu M, Weinberg O, Rao JY, Brooks MN. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 2006 Dec; 27(12):2424-33. PMID: 16785249.
      View in: PubMed
    28. Márquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006 Feb 26; 246(1-2):91-100. PMID: 16388889.
      View in: PubMed
    29. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006 Jan-Feb; 8(1):36-42. PMID: 16362149.
      View in: PubMed
    30. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, Pietras RJ. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005 Dec 15; 65(24):11287-91. PMID: 16357134.
      View in: PubMed
    31. Pietras RJ, Levin ER, Szego CM. Estrogen receptors and cell signaling. Science. 2005 Oct 07; 310(5745):51-3; author reply 51-3. PMID: 16210518.
      View in: PubMed
    32. Weinberg OK, Marquez-Garban DC, Pietras RJ. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat. 2005 Aug; 8(4):219-33. PMID: 16054421.
      View in: PubMed
    33. Pietras RJ. Overview of the FASEB 2004 summer research conference on steroid hormone receptors: integration of plasma membrane and nuclear-initiated signaling in hormone action. Steroids. 2005 May-Jun; 70(5-7):345-6. PMID: 15862815.
      View in: PubMed
    34. Pietras RJ, Márquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 2005 May-Jun; 70(5-7):372-81. PMID: 15862820.
      View in: PubMed
    35. Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. Targeted therapy: wave of the future. J Clin Oncol. 2005 Mar 10; 23(8):1776-81. PMID: 15755985.
      View in: PubMed
    36. Pietras RJ, Weinberg OK. Antiangiogenic Steroids in Human Cancer Therapy. Evid Based Complement Alternat Med. 2005 Mar; 2(1):49-57. PMID: 15841278.
      View in: PubMed
    37. Garbán HJ, Márquez-Garbán DC, Pietras RJ, Ignarro LJ. Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci U S A. 2005 Feb 15; 102(7):2632-6. PMID: 15699347; PMCID: PMC548976.
    38. Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005; 93 Suppl 1:S11-8. PMID: 16247595.
      View in: PubMed
    39. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004 May 19; 96(10):739-49. PMID: 15150302.
      View in: PubMed
    40. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J. 2003 Sep-Oct; 9(5):361-73. PMID: 12968955.
      View in: PubMed
    41. Nemere I, Pietras RJ, Blackmore PF. Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem. 2003 Feb 15; 88(3):438-45. PMID: 12532320.
      View in: PubMed
    42. Li D, Williams JI, Pietras RJ. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene. 2002 Apr 25; 21(18):2805-14. PMID: 11973639.
      View in: PubMed
    43. Pietras RJ, Nemere I, Szego CM. Steroid hormone receptors in target cell membranes. Endocrine. 2001 Apr; 14(3):417-27. PMID: 11444440.
      View in: PubMed